About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Ohio | 763 Studies

Clinical Trials LymphomaOhio

Lymphoma Clinical Trials in Ohio

Find 763 clinical trials for lymphoma near Ohio. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 181-200 of 763 trials

Active not recruitingA Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab…NCT04970901·Clovis, California and 39 others

PreviousPage 10 of 39Next

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedA Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with…NCT03372057·Duarte, California and 35 others

Completed3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaThis phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma.NCT00293345·Columbus, Ohio

Approved for marketingStudy of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesThe primary objectives of this study are: Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell…NCT04162756·Stanford, California and 8 others

TerminatedEfficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisThe primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with…NCT03738423·Birmingham, Alabama and 88 others

RecruitingTagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesTagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic…NCT05476770·Los Angeles, California and 30 others

TerminatedReduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's LymphomaRATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells.NCT00057954·Aurora, Colorado and 18 others

CompletedAlisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaThis is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered…NCT01482962·Birmingham, Alabama and 150 others

TerminatedA Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesThe purpose of this study is to evaluate the safety, tolerability, dose-limiting toxicities (any harmful effect of a drug) (DLT), maximum tolerated dose (MTD), recommended Phase 2…NCT02454270·Detroit, Michigan and 19 others

Active not recruitingInotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaThis phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that…NCT02981628·Birmingham, Alabama and 156 others

RecruitingA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaThis is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in…NCT07123454·Irvine, California and 22 others

Enrolling by invitationLong-Term Follow-up StudyThis is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical…NCT05332054·Birmingham, Alabama and 30 others

CompletedA Study Evaluating CPI-1205 in Patients With B-Cell LymphomasFirst in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas.NCT02395601·Lafayette, Indiana and 5 others

CompletedA Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaThis Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in…NCT03274492·Birmingham, Alabama and 208 others

CompletedStudy to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesThe purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally…NCT02924402·La Jolla, California and 22 others

CompletedPersistent Postpartum Cardiovascular Dysfunction in Patients With PreeclampsiaThe investigators plan to enroll women with PE prospectively to evaluate incremental cardiovascular risk in those who have PE with severe features.NCT04063397·Columbus, Ohio

CompletedChemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00002676·Scottsdale, Arizona and 20 others

CompletedStudy to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to RituximabThis was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability…NCT02747043·Encinitas, California and 97 others

CompletedDouble Cord Versus Haploidentical (BMT CTN 1101)Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma.NCT01597778·Birmingham, Alabama and 38 others

TerminatedSafety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's LymphomaThe purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan…NCT00057343·Huntsville, Alabama and 66 others

Other Conditions in Ohio

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia